Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.

IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pharmacology Pub Date : 2023-01-01 Epub Date: 2023-07-17 DOI:10.1159/000531319
Agata Czarnywojtek, Magdalena Borowska, Kamil Dyrka, Stefaan Van Gool, Nadia Sawicka-Gutaj, Jakub Moskal, Jeremi Kościński, Patryk Graczyk, Tomasz Hałas, Agnieszka Marta Lewandowska, Rafał Czepczyński, Marek Ruchała
{"title":"Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.","authors":"Agata Czarnywojtek,&nbsp;Magdalena Borowska,&nbsp;Kamil Dyrka,&nbsp;Stefaan Van Gool,&nbsp;Nadia Sawicka-Gutaj,&nbsp;Jakub Moskal,&nbsp;Jeremi Kościński,&nbsp;Patryk Graczyk,&nbsp;Tomasz Hałas,&nbsp;Agnieszka Marta Lewandowska,&nbsp;Rafał Czepczyński,&nbsp;Marek Ruchała","doi":"10.1159/000531319","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma multiforme (GBM) is a WHO grade 4 glioma and the most common malignant primary brain tumour. Recently, there has been outstanding progress in the treatment of GBM. In addition to the newest form of GBM removal using fluorescence, three-dimensional (3D) imaging, tomoradiotherapy, moderate electro-hyperthermia, and adjuvant temozolomide (post-operative chemotherapy), new developments have been made in the fields of immunology, molecular biology, and virotherapy. An unusual and modern treatment has been created, especially for stage 4 GBM, using the latest therapeutic techniques, including immunotherapy and virotherapy. Modern oncological medicine is producing extraordinary and progressive therapeutic methods. Oncological therapy includes individual analysis of the properties of a tumour and targeted therapy using small-molecule inhibitors. Individualised medicine covers the entire patient (tumour and host) in the context of immunotherapy. An example is individualised multimodal immunotherapy (IMI), which relies on individual immunological tumour-host interactions. In addition, IMI is based on the concept of oncolytic virus-induced immunogenic tumour cell death.</p><p><strong>Summary: </strong>In this review, we outline current knowledge of the various available treatment options used in the therapy of GBM including both traditional therapeutic strategy and modern therapies, such as tomotherapy, electro-hyperthermia, and oncolytic virotherapy, which are promising treatment strategies with the potential to improve prognosis in patients with GBM.</p><p><strong>Key messages: </strong>This newest therapy, immunotherapy combined with virotherapy (oncolytic viruses and cancer vaccines), is displaying encouraging signs for combating GBM. Additionally, the latest 3D imaging is compared to conventional two-dimensional imaging.</p>","PeriodicalId":20209,"journal":{"name":"Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000531319","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Glioblastoma multiforme (GBM) is a WHO grade 4 glioma and the most common malignant primary brain tumour. Recently, there has been outstanding progress in the treatment of GBM. In addition to the newest form of GBM removal using fluorescence, three-dimensional (3D) imaging, tomoradiotherapy, moderate electro-hyperthermia, and adjuvant temozolomide (post-operative chemotherapy), new developments have been made in the fields of immunology, molecular biology, and virotherapy. An unusual and modern treatment has been created, especially for stage 4 GBM, using the latest therapeutic techniques, including immunotherapy and virotherapy. Modern oncological medicine is producing extraordinary and progressive therapeutic methods. Oncological therapy includes individual analysis of the properties of a tumour and targeted therapy using small-molecule inhibitors. Individualised medicine covers the entire patient (tumour and host) in the context of immunotherapy. An example is individualised multimodal immunotherapy (IMI), which relies on individual immunological tumour-host interactions. In addition, IMI is based on the concept of oncolytic virus-induced immunogenic tumour cell death.

Summary: In this review, we outline current knowledge of the various available treatment options used in the therapy of GBM including both traditional therapeutic strategy and modern therapies, such as tomotherapy, electro-hyperthermia, and oncolytic virotherapy, which are promising treatment strategies with the potential to improve prognosis in patients with GBM.

Key messages: This newest therapy, immunotherapy combined with virotherapy (oncolytic viruses and cancer vaccines), is displaying encouraging signs for combating GBM. Additionally, the latest 3D imaging is compared to conventional two-dimensional imaging.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多型胶质母细胞瘤:最新诊断和治疗技术。
背景:多形性胶质母细胞瘤(GBM)是世界卫生组织4级胶质瘤,也是最常见的恶性原发性脑肿瘤。近年来,GBM的治疗取得了突出进展。除了使用荧光、三维(3D)成像、断层放射治疗、中等电热疗和辅助替莫唑胺(术后化疗)的最新形式的GBM去除外,免疫学、分子生物学和病毒治疗领域也取得了新的进展。使用最新的治疗技术,包括免疫疗法和病毒疗法,已经创造了一种不同寻常的现代治疗方法,尤其是针对4期GBM。现代肿瘤学正在产生非凡而进步的治疗方法。肿瘤治疗包括对肿瘤特性的个体分析和使用小分子抑制剂的靶向治疗。在免疫疗法的背景下,个体化药物涵盖整个患者(肿瘤和宿主)。一个例子是个体化多模式免疫疗法(IMI),它依赖于个体免疫肿瘤-宿主的相互作用。此外,IMI是基于溶瘤病毒诱导的免疫原性肿瘤细胞死亡的概念。摘要:在这篇综述中,我们概述了GBM治疗中使用的各种可用治疗方案的最新知识,包括传统治疗策略和现代治疗,如断层治疗、电热疗和溶瘤病毒治疗,这些都是有前景的治疗策略,有可能改善GBM患者的预后,免疫疗法结合病毒疗法(溶瘤病毒和癌症疫苗)正在显示出对抗GBM的令人鼓舞的迹象。此外,将最新的3D成像与传统的二维成像进行比较。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacology
Pharmacology 医学-药学
CiteScore
5.60
自引率
0.00%
发文量
52
审稿时长
6-12 weeks
期刊介绍: ''Pharmacology'' is an international forum to present and discuss current perspectives in drug research. The journal communicates research in basic and clinical pharmacology and related fields. It covers biochemical pharmacology, molecular pharmacology, immunopharmacology, drug metabolism, pharmacogenetics, analytical toxicology, neuropsychopharmacology, pharmacokinetics and clinical pharmacology. In addition to original papers and short communications of investigative findings and pharmacological profiles the journal contains reviews, comments and perspective notes; research communications of novel therapeutic agents are encouraged.
期刊最新文献
Eleclazine Suppresses Ventricular Fibrillation in Failing Rabbit Hearts with Ischemia- Reperfusion Injury Undergoing Therapeutic Hypothermia. Tanshinone IIA inhibits H2O2-induced ferroptosis in melanocytes through activating Nrf2 signaling pathway. UCF101 Rescues against Diabetes-Evoked Cardiac Remodeling and Contractile Anomalies through AMPK-Mediated Induction of Mitophagy. Rat Model of Menopausal/Andropausal Hypertension with Different Sensitivities to Non-Genomic Antihypertensive Responses of Female and Male Sex Steroids. Erratum.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1